SCHEMBL17844813

SCHEMBL17844813

Cc1ccc(S(=O)(=O)n2ccc3cnc(Cl)nc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.59
PKM P14618 2/20 0.49
BRD4 O60885 1/20 0.48
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.42
ALDH3A1 P30838 1/20 0.42
HTT P42858 1/20 0.42
NOD1 Q9Y239 1/20 0.42
RAPGEF4 Q8WZA2 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ALDH1A1 P00352 1/20 0.40
FGFR4 P22455 3/20 0.40
HTR6 P50406 1/20 0.38
HSD11B1 P28845 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30955697 0.86 CYP2C19 (0.58) L3MBTL1PKMBRD4ABL1BCR
SCHEMBL29229341 0.86 CYP2C19 (0.58) L3MBTL1PKMBRD4ABL1BCR
SCHEMBL31052371 0.83 L3MBTL1 (0.59) L3MBTL1PKMBRD4CYP2C19POLB
SCHEMBL31052347 0.81 L3MBTL1 (0.56) L3MBTL1PKMBRD4CYP2C19POLB
SCHEMBL29721737 0.80 L3MBTL1 (0.62) L3MBTL1PKMBRD4CYP2C19POLB
SCHEMBL14735293 0.80 L3MBTL1 (0.62) L3MBTL1PKMBRD4CYP2C19POLB
SCHEMBL14487894 0.80 L3MBTL1 (0.61) L3MBTL1PKMBRD4ABL1BCR
SCHEMBL27902479 0.80 HTT (0.53) L3MBTL1ABL1BCRPOLBALDH3A1
SCHEMBL2241097 0.79 L3MBTL1 (0.64) L3MBTL1PKMBRD4CYP2C19POLB
SCHEMBL19020570 0.78 L3MBTL1 (0.52) L3MBTL1PKMBRD4ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109608468-B Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业股份有限公司 2020-09-29 CN disclosed
CN-109608468-A Tofacitinib citrate impurity, and synthesis method and application thereof 成都倍特药业有限公司 2019-04-12 CN disclosed
CN-102711473-B Bruton's tyrosine kinase inhibitors 比奥根MA公司 2016-11-09 CN disclosed
WO-2016100349-A2 BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2016-06-23 WO disclosed
WO-2016100349-A2 BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2016-06-23 WO disclosed